Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of SHIELD THERAPEUTICS 5
No Price
Closing Price XLON 01.05.2026:
7,60 GBX
01.05.2026 15:14
Current Prices from SHIELD THERAPEUTICS 5
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
London
STX.L
GBX
01.05.2026 15:14
7,60 GBX
-1,15 GBX
-13,14 %
UTC
SHIEF
USD
30.04.2026 20:00
0,17 USD
0,00 USD
Share Float & Liquidity
Free Float39,27 %
Shares Float419,55 M
Shares Outstanding1,07 B
Company Profile for SHIELD THERAPEUTICS 5 Share
Shield Therapeutics plc, a specialty pharmaceutical company, engages in the development and commercialization of clinical stage pharmaceuticals to treat unmet medical needs. The company's lead product is Accrufer/Feraccru, a non-salt based oral therapy for the treatment of iron deficiency with or without anemia in adults. It also develops PT20, a novel iron-based phosphate binder that has completed its Phase II pivotal study for the treatment of hyperphosphatemia in patients with chronic kidney disease. The company was founded in 2008 and is based in Gateshead, the United Kingdom.
